Unichem Laboratories gets USFDA approval for Celecoxib capsules
On Wednesday, Unichem Laboratories Limited announced that it has received an abbreviated new drug application (ANDA) approval for its Celecoxib capsules 50 mg, 100 mg, 200 mg & 400 mg from United States Food & Drug Administration (USFDA).
Unichem will now be able to market a generic version of Celebrex capsules of GD Searle LLC, Division of Pfizer Inc. Celecoxib capsules are indicated for the treatment of osteoarthritis, juvenile rheumatoid arthritis (JRA), ankylosing spondylitis (AS), acute pain, and primary dysmenorrhea. The product will be commercialised from Unichem’s Goa plant, the company stated in its press release to BSE.
Unichem Laboratories is an integrated speciality company that manufactures and markets a large basket of pharmaceutical formulations as branded generics in several markets across the world.
On Wednesday, the stock of Unichem Laboratories Ltd closed at Rs 274.70, down by 1.06 per cent. It has a 52-week high of Rs 304.20 and a 52-week low of Rs 75.10 on BSE.